Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...
Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed versus analyst expectations, triggering a 50% stock drop and highlighting sector skepticism. Key hurdles for Compass ...
A synthetic form of the active ingredient in magic mushrooms has cleared an early-phase trial. The drug, Compass Pathways’ COMP360, came through the placebo-controlled phase 1 without setting off any ...
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Compass Pathways PLC CMPS said a White House executive order aimed at accelerating mental health treatment research could help speed access to its experimental psilocybin therapy, which the company ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Compass Pathways (NASDAQ:CMPS) is one of the small cap stocks with the highest upside potential. On April 24, Compass ...
Compass Pathways has filed paperwork for a Nasdaq IPO that will tee it up to take psilocybin therapy COMP360 through midphase development. Compass is developing psilocybin, the active ingredient in ...
PRINCETON, N.J.--(BUSINESS WIRE)--Certara ®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that the entire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results